Clinical Trial Update: CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating CD5-targeted CAR T-cell therapy for relapsed/refractory T-cell lymphomas is currently recruiting in Beijing (PTCL and CTCL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• CD5 CAR T-Cell Therapy

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL) | Phase 1, Phase 2 | Status: RECRUITING